Adora Ndu - 01 Jun 2023 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role
Director
Signature
/s/ Austin D. Kim, Attorney-in-Fact
Issuer symbol
ACAD
Transactions as of
01 Jun 2023
Transactions value $
$0
Form type
4
Filing time
05 Jun 2023, 21:43:44 UTC
Previous filing
14 Oct 2022
Next filing
16 Oct 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACAD Director Stock Options (Right to Buy) Award $0 +11K $0.00 11K 01 Jun 2023 Common Stock 11K $23.90 Direct F1
transaction ACAD Restricted Stock Units Award $0 +6.65K $0.00 6.65K 01 Jun 2023 Common Stock 6.65K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option shall vest quarterly over one year following the date of grant, with the final tranche vesting upon the earlier of one year following the date of grant or the next annual meeting date.
F2 Each restricted stock unit represents a contingent right to receive one share of Acadia common stock.
F3 The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date.